Since 2007, we create healthcare products to solve unmet medical needs by the use of the most advanced technology and a multidisciplinar approach.
Endor   Technologies   is   a   biotech   company   located   at   the   Barcelona   Science   Park   and   devoted   to   develop innovative   medical   treatments   for   Oncology    and   Dermatology,   based   on   the   use   of   the   most   advanced technology   and   a   multidisciplinar   approach.   Founded   in   2007   as   a   spin   off   of   the   Catalan   Institute   of Nanosciece   and   Nanotechnology   (ICN)   and   the   Catalan   Institution   for   Research   and   Advanced   Studies (ICREA),   n owadays   our   therapy   to   treat   pancreatic   and   colorectal   cancer   is   facing   phase   II   clinical trials.   The   Dermatological   R&D   Program   has   produced   a   new   active   ingredient   with   a   wide   number   of medical and dermocosmetic applications, most of them already into the market.
A Medical Company Oncology
THE PROBLEM Current   orthodoxy   in   oncological   sciences   is   based   on   the   study   of   mutated   genes   of   tumor cells   and   how   to   affect   these   mutations   to   obtain   a   therapeutic   effect.   However,   the discovery   that even   among   the   cells   of   the   same   tumor   exist   a   wide   genetic   hetereogeneity has   questioned   this   therapeutic   approach.   It   has   been   demonstrated   that   the   targeted gene   therapies   usually   produce   transitory   responses   that   are   finally   defeated   by the evolution of cell adaptations .
THE INNOVATION During   the   last   decades,   cancer   treatments   have   been   built   on   the   assumption   that   every cell   has   the   same   proliferative   behaviour   with   independece   of   its   position   into   the   tumor structure.   And   it’s   this   global   proliferation   what   causes   the   tumor   growth.   However,   more accurate   tumor   models   developed   during   the   last   decade   have   demonstrated   that   the tumor   uses   more   sophisticated   biological   mechanisms   to   displace   healthy   tissue and grow.
A MULTIDISCIPLINARY APPROACH TO CANCER Every   solid   tumor   borns   within   a   healthy   organ   and   for   growing,   it   has   to   push   the   healthy tissue   to   gain   space.   At   the   same   time,   healthy   tissue   press   on   the   tumor   to   content   it.   In order   to   conquer   space,   the   tumor   has   an   extremely   effective   biological   mechanism: tumor   just   proliferate   where   the   pressure   performed   by   the   healthy   tissue   is weaker.    As    expected,    the    tumor    follows    the    way    of    minimum    energy    and consequently   the   most   efficient   path   to   grow .   These   regions   of   minimum   pressure are   located   on   the   tumor   surface.   More   specifically,   they   are   the   concavities   on   the tumor border where the healthy tissue can’t exercise pressure.
The treatment
In   order   to   stop   tumor   growth   is   necessary   to   find   out   a cell    which    would    be    able    to    occupy    the    concavities around   the   tumor   where   the   pressure   exercised   by   the healthy   tissue   is   weaker.   This   way   the   empty   space   that the   tumor   cells   need   to   proliferate   is   eliminated.   This role is asigned to a specific immune response. We    have    developed    a    new    treatment    to    induce    and sustain    an    intense    leucocytosis    by    which    the    tumor concavities     are     occuped.     Tumor     evolves     from     a proliferative    state    to    a    quiescent    one    and    finally    to necrotic. In   the   picture,   the   border   between   the   healthy   tissue (A)    and    the    tumor    (B)    is    highlighted    in    red.    It’s confirmed   how   a   specific   type   of   leucocyte   infiltrates   to take    up    concavities    on    the    border    and    make    the pressure effective.
The   treatment   has   been   widely   verified   in   preclinical   models   in   terms   of   efficacy   and   security.   Clinical evidences   of   efficacy   have   been   reported   and   the   treatments   for   pancreatic   and   colorectal   cancer   are facing phase II of clinical trials , the last stage before licensing out.
Dermatology
We have developed a new active ingredient that affects the biological mechanisms by which cells live: migration, proliferation and extracellular matrix regeneration. These biological responses play a decisive role in skin regeneration. Therefore, a wide number of medical and dermocosmetic applications can be built on this innovative material.

ECM Regeneration

Collagen and Hyaluronic Acid are measured in volunteers. After 28 days, their increase is 34% in epidermis (intense green band) and 38% in dermis (space below the epidermis).

Cell Migration

After 12 h, treated cells close the separation between them.
The first application of this technology is the dermocosmetic collection Y.en Effect
Key Collaborators
BARCELONA SCIENCE PARK The Parc Científic de Barcelona offers institutions and companies an ideal environment dedicated to the generation, transfer and addition of value in the field of the life sciences. A cluster with a wide range of scientific and technological support.
EUROPEAN MEDICINES AGENCY The European Medicines Agency's (EMA) main responsibility is the protection and promotion of public and animal health, through the evaluation and supervision of medicines for human and veterinary use. Endor is member of the SME Program of EMA.
CENTRE FOR THE DEVELOPMENT OF INDUSTRIAL TECHNOLOGY The Centre for the Development of Industrial Technology (CDTI) is a Public Business Entity, answering to the Ministry of Economy, which fosters the technological development and innovation of Spanish companies.
ENDOR TECHNOLOGIES Barcelona Science Park Helix Building Baldiri Reixac St. 15 08028, Barcelona Spain info@endornanotech.com t: +34 934 020 468
Since 2007, we create healthcare products to solve unmet medical needs by the use of the most advanced technology and a multidisciplinar approach.   	Our research areas are Oncology and Dermatology. 	Founded in 2007 as a spin off of the Catalan Institute of Nanosciece and Nanotechnology (ICN) and the Catalan Institution for Research and Advanced Studies (ICREA). 	Pancreatic and Colorectal cancer treatments: Phase II Clinical Trials. 	New active ingredient from the Dermatological Program with extensive applications in medicine. Currently on the market. A Medical Company Oncology
THE PROBLEM The   discovery   that even   among   the   cells   of   the   same   tumor   exist   a   wide genetic   hetereogeneity   has   questioned   this   therapeutic   approach   of   gene therapies.    It    has    been    demonstrated    that    the    targeted    gene therapies   usually   produce   transitory   responses   that   are   finally defeated by the evolution of cell adaptations .
THE INNOVATION During   the   last   decades,   cancer   treatments   have   been   built   on   the assumption   that   every   cell   has   the   same   proliferative   behaviour   with independece   of   its   position   into   the   tumor   structure,   and   it’s   these   global proliferation   what   causes   the   tumor   growth.   But   more   accurate   tumor models   developed   during   the   last   decade   have   demonstrated   that   the tumor     uses     more     sophisticated     biological     mechanisms     to displace healthy tissue and grow.
A NEW WAY TO UNDERSTAND CANCER Every   solid   tumor   borns   within   a   healthy   organ   and   for   growing,   it   has to   push   the   healthy   tissue   to   gain   space.   In   order   to   conquer   space,   the tumor   has   an   extremely   effective   biological   mechanism:   tumor   just proliferate   where   the   pressure   performed   by   the   healthy   tissue is   weaker.   These   regions   of   minimum   pressure   are   located   on   the tumor   surface.   More   specifically,   they   are   the   concavities   on   the tumor border where the healthy tissue can’t exercise pressure.
The treatment
In   order   to   stop   tumor   growth   is   necessary   to   find   out   a   cell   which would   be   able   to   occupy   the   concavities   around   the   tumor   where   the pressure   exercised   by   the   healthy   tissue   is   weaker.   This   way   the   empty space   that   the   tumor   cells   use   to   proliferate   is   eliminated.   This   role   is asigned to a specific immune response. We   have   developed   a   new   treatment   to   induce   and   sustain   an   intense leucocytosis   by   which   the   tumor   concavities   are   occuped.   Tumor   evolves from a proliferative state to a quiescent one and finally to necrotic. In   the   picture,   the   border   between   the   healthy   tissue   (A)   and   the   tumor (B)    is    highlighted    in    red.    It’s    confirmed    how    specific    leucocytes infiltrates   to   take   up   concavities   on   the   border   and   make   the   pressure effective.
The    treatment    has    been    widely    verified    in    preclinical    models    with outstanding   results   in   terms   of   efficacy   and   security.   Clinical   evidences of   efficacy   have   been   reported   and   the   candidates   for   pancreatic   and colorectal   cancer   are   facing   phase   II   of   clinical   trials ,   the   last stage before licensing out.
Dermatology
We have developed a new active ingredient that affects the biological mechanisms by which cells live: migration, proliferation and extracellular matrix regeneration. These biological responses play a decisive role in skin regeneration. Therefore, a wide number of medical applications can be built on this innovative material.

ECM Regeneration

Collagen and Hyaluronic Acid are measured in volunteers. After 28 days, the increase is 34% in epidermis (green band above) and 38% in dermis (space below the epidermis).

Cell Migration

After 12 h, treated cells close the separation between them.
The first application of this technology is the dermocosmetic collection Y.en Effect
Key Collaborators
ENDOR NANOTECHNOLOGIES Barcelona Science Park Helix Building Baldiri Reixac St. 15 08028, Barcelona Spain info@endornanotech.com t: +34 934 020 468
Since 2007, we create healthcare products to solve unmet medical needs by the use of the most advanced technology and a multidisciplinar approach.
Endor   Technologies   is   a   biotech   company   located   at   the   Barcelona   Science   Park   and   devoted   to   develop innovative   medical   treatments   for   Oncology    and   Dermatology,   based   on   the   use   of   the   most   advanced technology   and   a   multidisciplinar   approach.   Founded   in   2007   as   a   spin   off   of   the   Catalan   Institute   of Nanosciece   and   Nanotechnology   (ICN)   and   the   Catalan   Institution   for   Research   and   Advanced   Studies (ICREA),   n owadays   our   therapy   to   treat   pancreatic   and   colorectal   cancer   is   facing   phase   II   clinical trials.   The   Dermatological   R&D   Program   has   produced   a   new   active   ingredient   with   a   wide   number   of medical and dermocosmetic applications, most of them already into the market.
A Medical Company Oncology
THE PROBLEM Current   orthodoxy   in   oncological   sciences   is   based   on   the   study   of   mutated   genes   of   tumor cells   and   how   to   affect   these   mutations   to   obtain   a   therapeutic   effect.   However,   the discovery   that even   among   the   cells   of   the   same   tumor   exist   a   wide   genetic   hetereogeneity has   questioned   this   therapeutic   approach.   It   has   been   demonstrated   that   the   targeted gene   therapies   usually   produce   transitory   responses   that   are   finally   defeated   by the evolution of cell adaptations .
THE INNOVATION During   the   last   decades,   cancer   treatments   have   been   built   on   the   assumption   that   every cell   has   the   same   proliferative   behaviour   with   independece   of   its   position   into   the   tumor structure.   And   it’s   this   global   proliferation   what   causes   the   tumor   growth.   However,   more accurate   tumor   models   developed   during   the   last   decade   have   demonstrated   that   the tumor   uses   more   sophisticated   biological   mechanisms   to   displace   healthy   tissue and grow.
A MULTIDISCIPLINARY APPROACH TO CANCER Every   solid   tumor   borns   within   a   healthy   organ   and   for   growing,   it   has   to   push   the   healthy tissue   to   gain   space.   At   the   same   time,   healthy   tissue   press   on   the   tumor   to   content   it.   In order   to   conquer   space,   the   tumor   has   an   extremely   effective   biological   mechanism: tumor   just   proliferate   where   the   pressure   performed   by   the   healthy   tissue   is weaker.    As    expected,    the    tumor    follows    the    way    of    minimum    energy    and consequently   the   most   efficient   path   to   grow .   These   regions   of   minimum   pressure are   located   on   the   tumor   surface.   More   specifically,   they   are   the   concavities   on   the tumor border where the healthy tissue can’t exercise pressure.
The treatment
In   order   to   stop   tumor   growth   is   necessary   to   find   out   a cell    which    would    be    able    to    occupy    the    concavities around   the   tumor   where   the   pressure   exercised   by   the healthy   tissue   is   weaker.   This   way   the   empty   space   that the   tumor   cells   need   to   proliferate   is   eliminated.   This role is asigned to a specific immune response. We    have    developed    a    new    treatment    to    induce    and sustain    an    intense    leucocytosis    by    which    the    tumor concavities     are     occuped.     Tumor     evolves     from     a proliferative    state    to    a    quiescent    one    and    finally    to necrotic. In   the   picture,   the   border   between   the   healthy   tissue (A)    and    the    tumor    (B)    is    highlighted    in    red.    It’s confirmed   how   a   specific   type   of   leucocyte   infiltrates   to take    up    concavities    on    the    border    and    make    the pressure effective.
The   treatment   has   been   widely   verified   in   preclinical   models   in   terms   of   efficacy   and   security.   Clinical evidences   of   efficacy   have   been   reported   and   the   treatments   for   pancreatic   and   colorectal   cancer   are facing phase II of clinical trials , the last stage before licensing out.
Dermatology
We have developed a new active ingredient that affects the biological mechanisms by which cells live: migration, proliferation and extracellular matrix regeneration. These biological responses play a decisive role in skin regeneration. Therefore, a wide number of medical and dermocosmetic applications can be built on this innovative material.

ECM Regeneration

Collagen and Hyaluronic Acid are measured in volunteers. After 28 days, their increase is 34% in epidermis (intense green band) and 38% in dermis (space below the epidermis).

Cell Migration

After 12 h, treated cells close the separation between them.
The first application of this technology is the dermocosmetic collection Y.en Effect
Key Collaborators
BARCELONA SCIENCE PARK The Parc Científic de Barcelona offers institutions and companies an ideal environment dedicated to the generation, transfer and addition of value in the field of the life sciences. A cluster with a wide range of scientific and technological support.
EUROPEAN MEDICINES AGENCY The European Medicines Agency's (EMA) main responsibility is the protection and promotion of public and animal health, through the evaluation and supervision of medicines for human and veterinary use. Endor is member of the SME Program of EMA.
CENTRE FOR THE DEVELOPMENT OF INDUSTRIAL TECHNOLOGY The Centre for the Development of Industrial Technology (CDTI) is a Public Business Entity, answering to the Ministry of Economy, which fosters the technological development and innovation of Spanish companies.
ENDOR TECHNOLOGIES Barcelona Science Park Helix Building Baldiri Reixac St. 15 08028, Barcelona Spain info@endornanotech.com t: +34 934 020 468
ES
EN
ES
EN